Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and Ocugen (NASDAQ:OCGN – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Creative Medical Technology and Ocugen”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Creative Medical Technology | $3,000.00 | 1,454.86 | -$5.99 million | ($2.07) | -0.32 |
| Ocugen | $4.41 million | 55.29 | -$67.85 million | ($0.26) | -2.77 |
Creative Medical Technology has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for Creative Medical Technology and Ocugen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Creative Medical Technology | 1 | 0 | 1 | 0 | 2.00 |
| Ocugen | 1 | 0 | 4 | 0 | 2.60 |
Ocugen has a consensus price target of $9.50, suggesting a potential upside of 1,221.28%. Given Ocugen’s stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Creative Medical Technology.
Risk and Volatility
Creative Medical Technology has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500.
Profitability
This table compares Creative Medical Technology and Ocugen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Creative Medical Technology | N/A | -86.52% | -81.96% |
| Ocugen | N/A | -127,987.80% | -115.95% |
Institutional and Insider Ownership
1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Ocugen beats Creative Medical Technology on 7 of the 13 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
About Ocugen
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
